Updated
Updated · The Washington Post · Nov 17
Mvix Slows Early Alzheimer’s Decline by Nearly 33% in 40% of Patients
Updated
Updated · The Washington Post · Nov 17

Mvix Slows Early Alzheimer’s Decline by Nearly 33% in 40% of Patients

1 articles · Updated · The Washington Post · Nov 17

Summary

  • More than 1,500 patients were studied for a year, and Mvix slowed mental decline by nearly a third in early Alzheimer’s patients not already taking other dementia drugs.
  • About 40% of participants fell into that subgroup; after 12 months, their decline lagged the placebo group by roughly 3.5 months on measures of memory, judgment and daily functioning.
  • The benefit vanished in the full trial because the other 60%—patients already on standard dementia medicines—showed little to no added improvement, leaving a key question about drug interactions or disease stage.
  • AriBio says the study still met its prespecified main goal and plans FDA talks on whether the data can support approval without another trial.
  • If cleared, low-dose Mvix would become the first U.S.-approved pill to slow Alzheimer’s, offering an oral alternative to antibody treatments that require infusions or injections and can cause brain swelling or bleeding.

Insights

Why did a repurposed erectile dysfunction pill only slow Alzheimer's in patients rejecting standard treatments?
Could a simple daily pill replace risky brain infusions for treating early-stage Alzheimer's disease?
Will the FDA approve a breakthrough dementia drug that failed 60% of its trial participants?